logo-loader
ImmuPharma PLC

ImmuPharma updates status of talks over lead drug alongside reorganisation

The firm remains in conversation with potential commercial partners as well as its regulatory advisors

researcher at a microscope
The company is still exploring the options for its lead drug

ImmuPharma PLC (LON:IMM) has confirmed it remains in negotiations with potential corporate partners for its lead drug Lupuzor, which has been developed to treat the auto-immune disease lupus.

It also said it is consulting with regulatory advisors on "potential pathways to market".

This follows the not wholly successful conclusion of phase III trials last year, though ImmuPharma believes the drug has market potential.

But, while talks with putative partners and advisors take place, the firm has put on hold a managed access programme for Lupuzor.

An extension study of the drug, meanwhile, is on track to report results this quarter.

Looking at the company’s other activities, management has decided to merge the France-based Elro Pharma and Ureka businesses “with a view to securing external investment either from private equity or through a public listing”.

“This in turn would allow ImmuPharma to focus on Lupuzor and the overall P140 platform for different autoimmune indications,” it added.

Finally, collaboration discussions with a company called Incanthera Limited have ended.

The shares rose 3% to 10.08p.

----adds share price----

Quick facts: ImmuPharma PLC

Price: £0.10

Market: AIM
Market Cap: £16.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Immupharma chairman details £2.66mln financing and open label extension study

ImmuPharma PLC’s (LON:IMM) chairman Tim McCarthy caught up with Proactive London's Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability. McCarthy says the six month extension study confirmed its outstanding and robust...

on 4/7/19

2 min read